Linking fms-like tyrosine kinase 3 and urokinase signalling to survivin expression in experimental arthritis

Andersson, Sofia
2014-03-07T09:25:02Z
2014-03-07T09:25:02Z
2014-03-07
Rheumatoid arthritis (RA) is a systemic autoimmune joint disease, in which chronic inflammation and hyperplastic synovial tissue mediates destruction of cartilage and bone. Survivin is known as an intracellular inhibitor of apoptosis and a positive regulator of cell division. Previous studies have shown that extracellular survivin can be detected in blood and synovial fluid from patients diagnosed with RA and that survivin in blood can predict destructive course of arthritis and poor response to anti-rheumatic treatment. The role of survivin in arthritis, the cellular source and processes leading to the release of survivin are far from understood. Two proteins, the differentiation factor Fms-like tyrosine kinase 3 ligand (Flt3L) and the Urokinase plasminogen activator (uPA) were positively associated to survivin in rheumatoid arthritis patients. The aim of this thesis was to investigate the role of Flt3 signalling for survivin production for arthritis development using the mBSA arthritis model and the role of survivin and urokinase signalling for the arthritogenic properties of synovial fibroblasts. Intracellular survivin expression was evaluated in the mBSA arthritis model after Flt3 activation with Flt3L or inhibition using or an Flt3 inhibitor, sunitinib. Changes in the frequencies of immune cell populations and the effect on arthritis development were evaluated after Flt3 inhibition. In addition, RNA silencing was used to directly target survivin in in vitro and in a human/SCID chimera model to study the impact of survivin on the arthritogenic properties of fibroblasts. The results presented in this thesis show that survivin is expressed in bone marrow and DCs in response to activation of the receptor tyrosine kinase Flt3 in vivo. Inhibition of Flt3 reduces survivin production, dendritic cell formation and synovial inflammation. uPA release from fibroblasts is survivin dependent and silencing of survivin in human fibroblasts reduced cartilage destruction in the knee joints of SCID mice. In conclusion, survivin may enhance the survival of antigen presenting dendritic cells and the arthritogenic properties of synovial fibroblasts in the RA joint.sv
2014-03-13
torsdagen den 13 mars 2014 kl. 09.00sv
Institute of Medicine. Department of Rheumatology and Inflammation Researchsv
SA
sofia.andersson@rheuma.gu.sesv
University of Gothenburg. Sahlgrenska Academysv
978-91-628-8920-3
http://hdl.handle.net/2077/34820
engsv
I. Andersson, SE, Svensson MN, Erlandsson MC, Dehlin M, Andersson KM, Bokarewa MI. Activation of Fms-like tyrosine kinase 3 signaling enhances survivin expression in a mouse model of rheumatoid arthritis. PlosOne 2012;7(10) ::PMID::23082191sv
II. Dehlin, M., Andersson S, Erlandsson M, Brisslert M, and Bokarewa M. Inhibition of fms-like tyrosine kinase 3 alleviates experimental arthritis by reducing formation of dendritic cells and antigen presentation. J Leukoc Biol 2011; 90:811-817. ::PMID::21771900sv
III. Baran, M., L. N. Mollers, S. Andersson, I. M. Jonsson, A. K. Ekwall, J. Bjersing, A. Tarkowski, and M. Bokarewa. Survivin is an essential mediator of arthritis interacting with urokinase signalling. J Cell Mol Med 2009; 13:3797-3808. ::PMID::19298527sv
survivinsv
rheumatoid arthritissv
dendritic cellssv
Flt3 ligandsv
Flt3sv
urokinasesv
uPARsv
Linking fms-like tyrosine kinase 3 and urokinase signalling to survivin expression in experimental arthritissv
texteng
Doctor of Philosophy (Medicine)sv
Doctoral thesiseng

Files

Original bundle

Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
gupea_2077_34820_4.pdf
Size:
104.03 KB
Format:
Adobe Portable Document Format
Description:
Abstract
Loading...
Thumbnail Image
Name:
gupea_2077_34820_6.pdf
Size:
3.33 MB
Format:
Adobe Portable Document Format
Description:
Thesis frame

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
4.68 KB
Format:
Item-specific license agreed upon to submission
Description: